Miyoshi Yasuhide, Uemura Koichi, Kawahara Takashi, Yoneyama Shuko, Hattori Yusuke, Teranishi Jun-Ichi, Ohta Jun-Ichi, Takebayashi Shigeo, Yokomizo Yumiko, Hayashi Narihiko, Yao Masahiro, Uemura Hiroji
Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Clin Genitourin Cancer. 2017 Aug;15(4):472-478. doi: 10.1016/j.clgc.2016.12.020. Epub 2016 Dec 29.
Bone scan index (BSI) is an objective tool for quantifying bone metastasis load. We assessed its prognostic usefulness in patients with metastatic castration-resistant prostate cancer (CRPC) treated with enzalutamide (ENZ) or abiraterone acetate (AA).
We analyzed 40 patients who received ENZ or AA treatment (ENZ/AA) for metastatic CRPC. The Cox proportional hazards model and a C-index were used to investigate associations between overall survival (OS) and BSI, and patient age, prostate-specific antigen, time to CRPC, previous docetaxel use, and pain.
Median OS after ENZ/AA was 17.8 months. All patient deaths (n = 19; 47.5%) were from prostate cancer. In multivariate analysis, decreased BSI was an independent predictor for longer OS (hazard ratio, 8.97; P = .011). Inclusion of BSI improved the C-index from 0.721 to 0.792 in predicting OS after ENZ/AA.
Decreased BSI after ENZ/AA independently predicts longer OS.
骨扫描指数（BSI）是一种用于量化骨转移负荷的客观工具。我们评估了其在接受恩杂鲁胺（ENZ）或醋酸阿比特龙（AA）治疗的转移性去势抵抗性前列腺癌（CRPC）患者中的预后价值。
我们分析了40例接受ENZ或AA治疗（ENZ/AA）的转移性CRPC患者。采用Cox比例风险模型和C指数来研究总生存期（OS）与BSI、患者年龄、前列腺特异性抗原、CRPC时间、既往多西他赛使用情况及疼痛之间的关联。
接受ENZ/AA治疗后的中位OS为17.8个月。所有患者死亡（n = 19；47.5%）均源于前列腺癌。在多变量分析中，BSI降低是OS延长的独立预测因素（风险比，8.97；P = 0.011）。纳入BSI后，预测ENZ/AA治疗后OS的C指数从0.721提高到0.792。
ENZ/AA治疗后BSI降低可独立预测更长的OS。
